References:
1. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Prim . 2018;4:18010. doi:10.1038/nrdp.2018.10
2. Famodu AA, Oduwa D. Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. Br J Biomed Sci . 1995;52(4):323-324.
3. Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol . 1980;33(7):622-625. doi:10.1136/jcp.33.7.622
4. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med . 2003;115(9):721-728. doi:10.1016/j.amjmed.2003.07.011
5. Westerman MP, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med . 1999;134(4):352-362. doi:10.1016/s0022-2143(99)90149-x
6. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica . 2009;94(11):1481-1484. doi:10.3324/haematol.2009.013672
7. Srisuwananukorn A, Raslan R, Zhang X, et al. Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.Blood Adv . 2020;4(9):1978-1986. doi:10.1182/bloodadvances.2019001384
8. Scarpato B, Strykowski R, Lawrence R, et al. Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease. Thromb Updat . 2022;6. doi:10.1016/j.tru.2022.100101
9. Naik RP, Streiff MB, Haywood C, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med . 2013;126(5):443-449. doi:10.1016/j.amjmed.2012.12.016
10. Brunson A, Keegan T, Mahajan A, White R, Wun T. High incidence of venous thromboembolism recurrence in patients with sickle cell disease.Am J Hematol . 2019;94(8):862-870. doi:10.1002/ajh.25508
11. O’Brien SH, Stanek JR, Witmer CM, Raffini L. The Continued Rise of Venous Thromboembolism Across US Children’s Hospitals.Pediatrics . 2022;149(3). doi:10.1542/peds.2021-054649
12. Betensky M, Kumar R, Hankins JS, Goldenberg NA. Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric hematologists. Thromb Res . 2022;211:133-139. doi:10.1016/j.thromres.2022.01.028
13. Children’s Hospitals’ Solutions for Patient Safety. SPS VTE prevention bundles.
14. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res . 2000;47(6):763-766. doi:10.1203/00006450-200006000-00013
15. Humes DJ, Nordenskjöld A, Walker AJ, West J, Ludvigsson JF. Risk of venous thromboembolism in children after general surgery. J Pediatr Surg . 2015;50(11):1870-1873. doi:10.1016/j.jpedsurg.2015.05.010
16. Manlhiot C, Brandão LR, Schwartz SM, et al. Management and Outcomes of Patients with Occlusive Thrombosis after Pediatric Cardiac Surgery.J Pediatr . 2016;169:146-153. doi:10.1016/j.jpeds.2015.10.046
17. Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost . 2010;8(1):202-204. doi:10.1111/j.1538-7836.2009.03678.x
18. Sharma R, Woods GM, Creary S, et al. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer . 2019;66(4):e27588. doi:10.1002/pbc.27588
19. Kumar R, Stanek J, Creary S, Dunn A, O’Brien SH. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: An administrative database study. Blood Adv . 2018;2(3):285-291. doi:10.1182/bloodadvances.2017012336
20. Raffini L, Huang Y-S, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics . 2009;124(4):1001-1008. doi:10.1542/peds.2009-0768
21. Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni M V. Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost . 2012;10(5):760-766. doi:10.1111/j.1538-7836.2012.04697.x
22. Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood . 2007;110(3):908-912. doi:10.1182/blood-2006-11-057604
23. Mekontso Dessap A, Deux J-F, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med . 2011;184(9):1022-1029. doi:10.1164/rccm.201105-0783OC
24. Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: What the anticoagulation expert needs to know. In:Journal of Thrombosis and Thrombolysis . Vol 35. ; 2013:352-358. doi:10.1007/s11239-013-0895-y
25. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med . 2000;342(25):1855-1865. doi:10.1056/NEJM200006223422502
26. Mahajerin A, Croteau SE. Epidemiology and risk assessment of pediatric venous thromboembolism. Front Pediatr . 2017;5(April):1-7. doi:10.3389/fped.2017.00068
27. Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications. J Pediatr Hematol Oncol . 1995;17(4):342-345. doi:10.1097/00043426-199511000-00011
28. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res . 2020;191:9-14. doi:10.1016/j.thromres.2020.04.024
29. Liem RI, Lanzkron S, Coates TD, et al. American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease. Blood Adv . 2019;3(23):3867-3897. doi:10.1182/bloodadvances.2019000916